Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
11.02
0.00 (0.00%)
Jul 16, 2025, 4:00 PM - Market closed

Verve Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
9844781,1211,1921,776-
Upgrade
Market Cap Growth
-63.46%-57.41%-5.95%-32.88%--
Upgrade
Enterprise Value
55697137211,389-
Upgrade
Last Close Price
11.025.6413.9419.3536.87-
Upgrade
PS Ratio
15.9214.7795.35614.13--
Upgrade
PB Ratio
2.070.971.872.164.97-
Upgrade
P/TBV Ratio
2.080.971.872.164.97-
Upgrade
EV/Sales Ratio
9.320.2760.61371.58--
Upgrade
Debt / Equity Ratio
0.140.140.130.150.01-
Upgrade
Asset Turnover
0.090.050.020.00--
Upgrade
Quick Ratio
9.5912.2917.0215.8416.379.86
Upgrade
Current Ratio
9.8412.6517.2416.0516.6710.11
Upgrade
Return on Equity (ROE)
-34.26%-36.36%-34.78%-34.66%-57.48%-136.07%
Upgrade
Return on Assets (ROA)
-19.35%-20.41%-19.48%-19.48%-23.53%-50.75%
Upgrade
Return on Capital (ROIC)
-21.73%-23.09%-21.34%-20.87%-25.88%-66.17%
Upgrade
Earnings Yield
-18.39%-41.61%-17.85%-13.20%-6.77%-
Upgrade
FCF Yield
-14.93%-33.81%-14.17%-11.37%-4.63%-
Upgrade
Buyback Yield / Dilution
-23.92%-32.02%-18.79%-101.04%-1094.26%-76.18%
Upgrade
Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q